CD38 and Miyoshi myopathy: Patients with triple-class refractory MM, defined as MM that is refractory to an IMiD, a PI, and an anti-CD38 MoAb, have a poor prognosis, with a median PFS of 3.4 months and a median OS of 9.3 months with subsequent theapies following withanti-CD38 MoAb failure [6].